We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lupus Candidate Benlysta Gets Thumbs Up From FDA Advisory Panel
Lupus Candidate Benlysta Gets Thumbs Up From FDA Advisory Panel
November 19, 2010
Despite questions over the drug’s efficacy and safety, an FDA advisory committee has voted 13–2 to recommend approval of Human Genome Sciences and GlaxoSmithKline’s Benlysta to reduce disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus.